Health Condition 1: F20- Schizophrenia Health Condition 2: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Adjunctive treatment by Selenium 200mcg: The intervention group would receive Capsule Selenium 200mcg per day, regularly for six weeks alongside treatment as usual
Control Interventio
Sponsors
Central Institute Of Psychiatry , Ranchi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female indoor patients satisfying the ICD 11 criteria of Schizophrenia 2. Illness duration of minimum 2 years. 3. Patients who are drug free/drug naive. 4. Those who give informed consent for participating in the study.
Exclusion criteria
Exclusion criteria: 1. Any other major comorbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine. 2. Current or past history of severe medical or neurological illness. 3. Known hypersensitivity to Selenium or any of its components. 4. Patients who had received ECT in the last six months. 5. Comorbid medical illness known to affect Selenium levels including acute or chronic inflammatory disorder and neurological disorder. 6. Patient on multivitamin supplementation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Significant effect of Cap. Selenium (200mcg) on positive and negative symptoms in patients with schizophrenia as compared to treatment as usual group. Timepoint: Baseline, 2nd week, 4th week and 6th week of intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Significant alteration of Glutamate, Glycine, N-Acetyl Aspartate, Creatinine concentrations in Anterior Cingulate Cortex as detected by MRS (Magnetic Resonance Spectroscopy)Timepoint: Baseline, 2nd week, 4th week and 6th week of intervention | — |
Countries
India
Contacts
Public ContactSantosh Kumar Sinha
Central Institute Of Psychiatry
Outcome results
None listed